RT Journal Article
SR Electronic
T1 Carbon-ion Radiotherapy for Prostate Cancer: Analysis of Morbidities and Change in Health-related Quality of Life
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5559
OP 5566
VO 35
IS 10
A1 ISHIKAWA, HITOSHI
A1 KATOH, HIROYUKI
A1 KAMINUMA, TAKUYA
A1 KAWAMURA, HIDEMASA
A1 ITO, KAZUTO
A1 MATSUI, HIROSHI
A1 HIRATO, JUNKO
A1 SHIMIZU, NOBUAKI
A1 TAKEZAWA, YUTAKA
A1 TSUJI, HIROSHI
A1 SUZUKI, KAZUHIRO
A1 OHNO, TATSUYA
A1 NAKANO, TAKASHI
A1 GROUP FOR GENITOURINARY TUMORS AT GUNMA HEAVY ION MEDICAL CENTER
YR 2015
UL http://ar.iiarjournals.org/content/35/10/5559.abstract
AB Aim: To prospectively evaluate the feasibility of carbon-ion radiotherapy (C-ion RT) for prostate cancer using a new compact-sized accelerator. Patients and Methods: Seventy-six patients underwent C-ion RT at our center using a recommended dose fractionation of 57.6 GyE in 16 fractions established at the National Institute of Radiological Sciences. Health-related Quality of Life (HRQOL) assessment was also performed using the Medical Outcome Study 8-items Short Form Health Survey (SF-8) questionnaire. Results: The median follow-up time was 51 months (range=8-58 months). Grade 2 gastrointestinal and genitourinary complications developed in 1 (1.3%) and 5 (6.6%) patients, respectively. Recurrences occurred in 4 patients, and the 4-year biochemical relapse-free rate was 94.6%. The HRQOL scores after C-ion RT were objectively well-maintained. Conclusion: Irrespective of the small number of patients of the study, C-ion RT for prostate cancer using the first commercial-based accelerator reproduced the toxicity outcomes at the NIRS.